FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Drug Interaction Labeling Guidance

FDA publishes a draft guidance with recommendations for the placement and content of drug interaction information in labeling for human drugs and biol...

latest-news-card-1
Biologics

Sangamo to Seek Accelerated OK on Gene Therapy

Sangamo Therapeutics reaches an agreement with FDA on a clear regulatory pathway to accelerated approval for the companys gene therapy candidate ST-92...

latest-news-card-1
Medical Devices

Its Official: Tarver Takes on CDRH Director Post

FDA names CDRH deputy director Michelle Tarver as the new Center director, replacing retiring head Jeff Shuren, who hand-picked his replacement.

latest-news-card-1
Medical Devices

New FDA Data Tool on Parkinsons

FDA says a new open-access dataset on gait patterns in patients with Parkinsons disease may lead to novel medical devices.

latest-news-card-1
Human Drugs

3 Stakeholders Nix Biosimilar PSGs

Three stakeholders tell FDA they oppose the idea of the agency developing product-specific guidances to promote biosimilar development.

latest-news-card-1
Medical Devices

Digital Health Advisory Committee AI Meeting Materials

FDA posts an executive summary and questions for discussion at a scheduled 11/20-21 meeting of its Digital Health Advisory Committee to discuss total ...

latest-news-card-1
Human Drugs

Lenz Therapeutics NDA Accepted for Farsightedness

FDA accepts for review a Lenz Therapeutics NDA for LNZ100 (aceclidine), an eyedrop medication for treating presbyopia.

latest-news-card-1
Human Drugs

Novo Nordisk to Seek Rybelsus Expanded Label

Novo Nordisk says it will submit a NDA supplement seeking an expanded label for its diabetes drug Rybelsus (semaglutide) based on data from the SOUL c...

latest-news-card-1
Federal Register

Pfizers Vyndagel Regulatory Review Period

Federal Register notice: FDA determines for patent term extension purposes the regulatory review period for Pfizers Vyndaqel (tafamidis meglumine).

latest-news-card-1
Human Drugs

NDA for Liver Cancer Combo Therapy Resubmitted

FDA accepts for review an Elevar Therapeutics NDA resubmission for its investigational drug rivoceranib, in combination with camrelizumab, as a first-...